Germany is considering purchasing the Russian-developed Sputnik V vaccine, contingent upon its approval by the European Medicines Agency (EMA). Chancellor Angela Merkel conveyed this intention, highlighting that a swift approval would make the acquisition of Sputnik V doses a sensible option for Germany's vaccination efforts.
However, the EMA's assessment is ongoing, with Merkel acknowledging that the agency currently lacks adequate information about the Sputnik V vaccine. This informational gap is a critical factor influencing the timeline for potential approval and subsequent procurement by Germany.
Merkel also addressed the scenario of a prolonged approval process. She noted that if the EMA's decision extends over several months, Germany's existing vaccine supply might become sufficient. In such a case, the necessity of ordering Sputnik V would be re-evaluated, considering the balance between supply and demand.
Furthermore, Merkel expressed optimism about the progress of Germany's vaccination campaign. She suggested that if vaccine availability continues to improve, the country might be able to lift its strict vaccination prioritization system as early as June. This would enable a broader segment of the population to schedule vaccination appointments, accelerating the overall immunization rate.
